Biosimilars are very similar versions of approved and authorized medicines. Clinically inactive components will have minor differences, but there are no significant differences between the biosimilar and the original product in terms of potency, purity and safety.
Protein biopharmaceuticals are being developed at an explosive rate and have attracted great inte...
Over the past decade, notable advances in the characterization and control of post translational modifications (PTMs) to enhance therapeutic properties have continued to drive the development of man...
"The LCMS 8060 is a highly useful and efficient instrument which can provide consistent and reliable..."Abraham Mathew Saji, BIOCARE MANUFACTURING SDN BHD
The liquid handling component of assay variability is often underappreciated or not directly measur...
.jpg.ashx?width=150&bgcolor=white)
